Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services / Medical Laboratories & Research
cytivalifesciences.com

See what CB Insights has to offer

Founded Year

2016

Stage

Acquired Unit | Acquired

Valuation

$0000 

About Cytiva

Cytiva, formerly GE Healthcare Life Sciences, is a provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics. Accelerating growth, productivity, and innovation in the sector are major strategic focus areas for the company, as global demand for personalized and advanced biological therapies is ever-increasing. Cytiva drives customer-centered innovation, from idea to commercial development stages, with facilities across Asia, Europe, and the Americas. It also has centers for customer collaboration and training to enable the development of new therapies, such as the Testa Center in Uppsala, Sweden and the University of Technology at Sydney.

Cytiva Headquarter Location

100 Results Way

Marlborough, Massachusetts, 01752,

United States

Latest Cytiva News

APAC region: Cytiva and Wego in capacity expansion move to support single-use technology trend

Sep 15, 2021

By Jane Byrne The two companies are expanding an existing facility jointly launched in 2018. They say newly added manufacturing lines will triple the supply capacity of single-use consumables in the Asia-Pacific region. The adoption of single-use technology is expected to increase rapidly in clinical production and in manufacturing, according to the BioPlan Annual Biomanufacturing report, which noted that more than 85% of current pre-commercial and clinical manufacturing lines/facilities are single-use. The planned expansion will consist of an additional eight new manufacturing lines, two of which are expected to launch by the end of 2021; with the other six lines scheduled in Q3 2022. It adds 1300 square meters to the manufacturing area of the ISO Class 7 cleanroom and also includes a 1200 square meters warehouse to further save lead time and increase flexibility for customers. Li Hua, general manager of Cytiva China, told us that “the increased capacity will help the region improve manufacturing resilience with shorter lead times, while maintaining the delivery of high-quality product to our customers within the broader region.”​ In addition, Cytiva said it is adding new products, 100L to 1,000L Xcellerex mixer bags, to the expanded facility’s manufacturing portfolio. They will incorporate Fortem technology – the company’s single-use characterized film. “Its local manufacture enhances our ability to provide business continuity for our customers.”​ Collaboration deemed critical to R&D efforts ​ “With the increase in global demand, customers require more flexibility and adaptability, resulting in the growing trend of domestic manufacturing, and Cytiva’s ‘In-region, for-region’ strategy meets these needs,​” said Francis Van Parys, vice president, Cytiva Asia Pacific. He also told BioPharma-Reporter about how the company is addressing the diverse needs in the region as well as supporting the exponential growth in research and development in Asian-Pacific markets. “According to the Global Biopharma Resilience Index, which Cytiva conducted in partnership with Financial Times company, Longitude, collaboration is the key driver of research and development in biopharma industry. ​ “One of the large-scale collaborations Cytiva supports in Asia-Pacific is the China-Singapore Guangzhou Knowledge City (CSGKC). CSGKC is an exemplary joint effort that brings together the governments of China and Singapore alongside thousands of commercial organizations within a single hub. Cytiva is fortunate to be involved in CSGKC’s development through its work with companies such as BeiGene, Lonza and Akesobio, in which we assisted in rapidly establishing manufacturing capabilities for these companies with our KUBio prefabricated biopharma facilities.​ “Additionally, Cytiva has Fast Trak centers and training centers in China, Korea, Japan, India and Singapore to support our customers in accelerating their research and development processes and enhancing capabilities and skills of local talent through our training and technical consultancy.”​ Copyright - Unless otherwise stated all contents of this web site are © 2021 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cytiva

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cytiva is included in 1 Expert Collection, including Infectious Disease.

I

Infectious Disease

2,222 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Cytiva Patents

Cytiva has filed 86 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Chromatography
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/17/2016

9/7/2021

Membrane technology, Pumps, Fluid dynamics, Filtration, Biotechnology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/17/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Membrane technology, Pumps, Fluid dynamics, Filtration, Biotechnology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.